Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Juno Therapeutics

Juno Therapeutics

Juno Therapeutics is a biopharmaceutical company developing medicines for the treatment of serious diseases.

Juno Therapeutics is a biopharmaceutical company focused on the development of clinical stage medicines for the treatment of serious diseases. The company was founded by Isabelle Rivière, Michael Jensen and Michel Sadelain in 2013 in Seattle, Washington, and was acquired by Celgene in January 2018.

Timeline

August 2014
Juno Therapeutics raises a $134,000,000 seed round from ARCH Venture Partners, Alaska Permanent Fund, Bezos Expeditions and Venrock.
April 2014
Juno Therapeutics raises a $145 series A round from ARCH Venture Partners, Alaska Permanent Fund, Bezos Expeditions and Venrock.
December 2013
Juno Therapeutics raises a $120,000,000 series A round from ARCH Venture Partners and Alaska Permanent Fund.
2013
Juno Therapeutics was founded by Isabelle Rivière, Michael Jensen, Michel Sadelain, Phil Greenberg, Renier Brentjens and Stan Riddell.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
May 20, 2021
BioSpace
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy - read this article along with other careers information, tips and advice on BioSpace
April 16, 2021
BioSpace
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.... - read this article along with other careers information, tips and advice on BioSpace
November 9, 2020
BioSpace
Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis - read this article along with other careers information, tips and advice on BioSpace
May 20, 2020
BioSpace
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases - read this article along with other careers information, tips and advice on BioSpace
May 15, 2020
BioSpace
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE
Golden logo
By using this site, you agree to our Terms & Conditions.